查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387432

血友病治疗市场报告：2030 年趋势、预测与竞争分析

Hemophilia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

血友病治疗的趋势与预测

预计到 2030 年，全球血友病治疗市场将达到约 184 亿美元，2024 年至 2030 年年复合成长率为 5.2%。市场的主要驱动因素是大量的血友病患者、血友病预防性治疗的可用性以及有利的政府配合措施。全球血友病治疗市场的未来看起来充满希望，A型血友病 A和B型血友病市场充满机会。

血友病治疗市场洞察

Lucintel 预测，由于可用的重组产品数量众多，重组凝血因子浓缩物预计在预测期内仍将是最大的细分市场。

由于血友病患者数量不断增加以及对先进技术产品的认识不断增强，预计欧洲在预测期内仍将是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球血友病治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球血友病治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球血友病治疗市场
    • A型血友病
    • B型血友病
  • 全球血友病药物治疗市场
    • 重组凝血因子浓缩物
    • 血浆衍生凝血因子浓缩物
    • 非因子替代疗法
  • 按最终用途分類的全球血友病治疗市场
    • 医院
    • 诊所
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球血友病治疗市场（按地区）
  • 北美血友病治疗市场
  • 欧洲血友病治疗市场
  • 亚太地区血友病治疗市场
  • 其他地区血友病治疗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球血友病治疗市场成长机会
    • 药物治疗的全球血友病治疗市场成长机会
    • 全球血友病治疗市场成长机会（依最终用途）
    • 按地区分類的全球血友病治疗市场成长机会
  • 全球血友病治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球血友病治疗市场的产能
    • 全球血友病治疗市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Baxter
  • Octapharma
  • CSL Limited
  • Grifols
  • Bayer
  • Pfizer
  • Sanofi
  • Ferring
  • BioMarin
  • Sangamo Therapeutics
简介目录

Hemophilia Treatment Trends and Forecast

The future of the global hemophilia treatment market looks promising with opportunities in the hemophilia A and hemophilia B markets. The global hemophilia treatment market is expected to reach an estimated $18.4 billion by 2030 with a CAGR of 5.2% from 2024 to 2030. The major drivers for this market are large numbers of hemophilia patients, usage of prophylactic treatment for hemophilia, and favorable government initiatives.

A more than 150-page report is developed to help in your business decisions.

Hemophilia Treatment by Segment

The study includes a forecast for the global hemophilia treatment by type, drug therapy, end use, and region.

Hemophilia Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Hemophilia A
  • Hemophilia B

Hemophilia Treatment Market by Drug Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Recombinant Coagulation Factor Concentrates Therapy
  • Plasma Derived Coagulation Factor Concentrates Therapy
  • Non-Factor Replacement Therapy

Hemophilia Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Clinics
  • Others

Hemophilia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Hemophilia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hemophilia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hemophilia treatment companies profiled in this report include-

  • Baxter
  • Octapharma
  • CSL Limited
  • Grifols
  • Bayer
  • Pfizer
  • Sanofi
  • Ferring
  • BioMarin
  • Sangamo Therapeutics

Hemophilia Treatment Market Insights

Lucintel forecasts that recombinant coagulation factor concentrates therapy will remain the largest segment over the forecast period because of the large number of recombinant technology products available for the treatment.

Europe will remain the largest region over the forecast period due to increasing number of hemophilic patients and rising awareness about technologically advanced products in the region.

Features of the Global Hemophilia Treatment Market

Market Size Estimates: Hemophilia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Hemophilia treatment market size by type, drug therapy, end use, and region in terms of value ($B).

Regional Analysis: Hemophilia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, drug therapy, end use, and regions for the hemophilia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hemophilia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the hemophilia treatment market size?

Answer: The global hemophilia treatment market is expected to reach an estimated $18.4 billion by 2030.

Q2. What is the growth forecast for hemophilia treatment market?

Answer: The global hemophilia treatment market is expected to grow with a CAGR of 5.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the hemophilia treatment market?

Answer: The major drivers for this market are large numbers of hemophilia patients, usage of prophylactic treatment for hemophilia, and favorable government initiatives.

Q4. What are the major segments for hemophilia treatment market?

Answer: The future of the global hemophilia treatment market looks promising with opportunities in the hemophilia A and hemophilia B markets.

Q5. Who are the key hemophilia treatment market companies?

Answer: Some of the key hemophilia treatment companies are as follows:

  • Baxter
  • Octapharma
  • CSL Limited
  • Grifols
  • Bayer
  • Pfizer
  • Sanofi
  • Ferring
  • BioMarin
  • Sangamo Therapeutics

Q6. Which hemophilia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that recombinant coagulation factor concentrates therapy will remain the largest segment over the forecast period because of the large number of recombinant technology products available for the treatment.

Q7. In hemophilia treatment market, which region is expected to be the largest in next 5 years?

Answer: Europe will remain the largest region over the forecast period due to increasing number of hemophilic patients and rising awareness about technologically advanced products in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the hemophilia treatment market by type (hemophilia A and hemophilia B), drug therapy (recombinant coagulation factor concentrates therapy, plasma derived coagulation factor concentrates therapy, and non-factor replacement therapy), end use (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Hemophilia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Hemophilia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Hemophilia Treatment Market by Type
    • 3.3.1: Hemophilia A
    • 3.3.2: Hemophilia B
  • 3.4: Global Hemophilia Treatment Market by Drug Therapy
    • 3.4.1: Recombinant Coagulation Factor Concentrates Therapy
    • 3.4.2: Plasma Derived Coagulation Factor Concentrates Therapy
    • 3.4.3: Non-Factor Replacement Therapy
  • 3.5: Global Hemophilia Treatment Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Clinics
    • 3.5.3: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Hemophilia Treatment Market by Region
  • 4.2: North American Hemophilia Treatment Market
    • 4.2.2: North American Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy
  • 4.3: European Hemophilia Treatment Market
    • 4.3.1: European Hemophilia Treatment Market by Type: Hemophilia A and Hemophilia B
    • 4.3.2: European Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy
  • 4.4: APAC Hemophilia Treatment Market
    • 4.4.1: APAC Hemophilia Treatment Market by Type: Hemophilia A and Hemophilia B
    • 4.4.2: APAC Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy
  • 4.5: ROW Hemophilia Treatment Market
    • 4.5.1: ROW Hemophilia Treatment Market by Type: Hemophilia A and Hemophilia B
    • 4.5.2: ROW Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Hemophilia Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Hemophilia Treatment Market by Drug Therapy
    • 6.1.3: Growth Opportunities for the Global Hemophilia Treatment Market by End Use
    • 6.1.4: Growth Opportunities for the Global Hemophilia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Hemophilia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Hemophilia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hemophilia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Baxter
  • 7.2: Octapharma
  • 7.3: CSL Limited
  • 7.4: Grifols
  • 7.5: Bayer
  • 7.6: Pfizer
  • 7.7: Sanofi
  • 7.8: Ferring
  • 7.9: BioMarin
  • 7.10: Sangamo Therapeutics